

Rationally Designed Short Polyisoprenol-Linked PglB Substrates for Engineered Polypeptide and Protein N-Glycosylation

Feng Liu,^{†,§} Balakumar Vijayakrishnan,^{†,§} Amirreza Faridmoayer,^{‡,§} Thomas A. Taylor,[†] Thomas B. Parsons,[†] Gonçalo J.L. Bernardes,[†] Michael Kowarik,[‡] and Benjamin G. Davis*,[†]

[†]Department of Chemistry, Chemistry Research Laboratory, Oxford University, Oxford OX1 3TA United Kingdom

[‡]GlycoVaxyn AG, 8952 Schlieren, Switzerland

§ Supporting Information

ABSTRACT: The lipid carrier specificity of the protein N-glycosylation enzyme *C. jejuni* PglB was tested using a logical, synthetic array of natural and unnatural C10, C20, C30, and C40 polyisoprenol sugar pyrophosphates, including those bearing repeating *cis*-prenyl units. Unusual, short, synthetically accessible C20 prenols (nerylnerol **1d** and geranylnerol **1e**) were shown to be effective lipid carriers for PglB sugar substrates. Kinetic analyses for PglB revealed clear K_M -only modulation with lipid chain length, thereby implicating successful *in vitro* application at appropriate concentrations. This was confirmed by optimized, efficient *in vitro* synthesis allowing >90% of Asn-linked β -N-GlcNAc-ylated peptide and proteins. This reveals a simple, flexible biocatalytic method for glycoconjugate synthesis using PglB N-glycosylation machinery and varied chemically synthesized glycosylation donor precursors.

Protein glycosylation is a vital co- or post-translational modification that links glycans to proteins typically through N- or O- linkages. Such modifications exist widely in eukaryotic and archaeal organisms and greatly expand the diversity of the proteome.^{1–3} While N-linked glycosylation had been believed to be absent in prokaryotic systems, the discovery of the protein N-glycosyltransferase PglB in Gram-negative bacterium *Campylobacter jejuni* highlighted greater diversity; PglB is responsible for glycosylating over 50 different proteins.^{4–7} Since then PglB orthologues have been found in *Campylobacter lari*,⁸ the *Helicobacter* genus (*H. pullorum*, *H. canadensis*, *H. winthamensis*)⁹ as well as *Desulfovibrio desulfuricans*¹⁰ and, very recently, *Methanococcus voltae*.¹¹ *In vivo* PglB uses a C55 undecaprenylpyrophosphate-linked oligosaccharide as its substrate and glycosylates the primary amide nitrogen of the asparagine side chain in a D/E-X-N-X-T/S consensus sequence (where X can be any amino acid except proline, Figure 1). In contrast to its eukaryotic counterpart Stt3p, PglB does not require other proteins/subunits and can apparently catalyze this N-glycosylation *in vivo* alone.¹² Moreover, *in vivo* biosynthetic studies that allowed exposure of PglB to other lipid-linked oligosaccharides have suggested a possibly relaxed specificity toward the nature of glycan substrate, as compared to the relatively highly specific eukaryotic N-glycosylation enzymes.¹³ Recent elegant approaches flexibly using PglB *in vivo* have been developed to prepare glycoproteins.^{14,15} These distinct characteristics of PglB, as well





Figure 1. Bacterial N-linked glycosylation and designed unnatural candidate polyisoprenols **1a–g** as alternative short lipid carriers for PglB-catalyzed glycosylation. The polyisoprenols were synthesized from building blocks **2a–d** and **3a** and **3b**.

as the fact that *C. jejuni* PglB can be readily overexpressed in functional form in *Escherichia coli*,¹⁶ highlight PglB's potential as a synthetic biocatalyst. They suggest it as a potentially ideal model from which to generate a ready synthetic system for *in vitro* protein glycosylation. However, the donor substrates used normally by PglB *in vivo* (C55 lipid pyrophosphoryl-linked oligosaccharides containing the rare, bacterial sugar bacillosamine (Bac)) would restrict this system (both in substrate accessibility and product relevance).

In an attempt to optimize the PglB protein N-glycosylation platform for practical, synthetic (and hence *in vitro*) use, we designed an array of chemically generated polyisoprenol variants to find those simpler and shorter than the natural undecaprenol (Figure 1) and that might serve as alternative lipid carriers that could be recognized by PglB. Insightful prior work has elucidated some aspects of the polyisoprenol specificity of PglB.^{17,18} However, estimated conversions for these reactions were $\leq 20\%$. In addition, many of these prior substrates were prepared enzymatically from polyisoprenols isolated from natural sources, enabling only nmol analysis of lipid pyrophosphates containing the natural *Campylobacter* (GalNAc-GalNAc-BacdiNac) gly-

Received: September 11, 2013

Published: December 16, 2013


Scheme 1. Syntheses of Polyprenol Variants^a

^a(i) BuLi, THF, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMTP), -78 °C. Yield: 4a = 92%, 4b = 93%, 4c = 83%, 4d = 63%, 4e = 67%, 4f = 74%. (ii) (1) TBAF, THF, RT, 4 h; (2) LiEt₃BH, (dppp)PdCl₂, THF, 0 °C–RT. Yield: 1a = 65%, 1b = 57%, 1c = 50%, 1d = 70%, 1e = 60%, 1f = 54%.

cans. This revealed tantalizing activity for two shorter (mixed *cis/trans* prenyl-9 and prenyl-8) variants. However, despite some individual pioneering examples^{19–28} synthetic access to other prenyls has been rare, and homologated families of lipids have not yet been probed. Therefore, with the intention of probing fuller lipid and sugar substrate plasticity and breadth in PglB and with the intention of creating synthetically accessible substrates, we first systematically varied the lipid carriers (Figure 1).

As a starting point for lipid variation, we speculated that the use of repeating *cis*-prenyl units at the hydroxyl terminus would confer binding affinity due to a resemblance to the alcohol-terminus that bears the glycan-pyrophosphate found in the natural substrate and likely enters a binding pocket in PglB.²⁹ This notion is supported by a crystal structure which has a Mg²⁺ bound at the active site.²⁹ Subsequent modeling suggested that the lipid carrier would likely locate first in a narrow pocket that would tightly accommodate two isoprenyl units (and thus impose tighter stereochemical requirements) and then along a broader hydrophobic groove with potentially more relaxed requirements (Figure S12). Thus, compounds 1a–g, all bearing one or more terminal repeating *cis*-prenyl units were designed and synthesized as primary candidate lipid carriers (Figure 1). In brief (see SI for further details), compounds 1a–f were synthesized from head (compound 3a and 3b) and tail building blocks (compound 2a–d). The requisite building blocks were prepared and elongated using coupling between appropriate sulfones and allyl chloride. Utilization of a convergent synthetic strategy in the case of long lipids (Scheme 1) allowed useful flexibility in the generation of lipids with different stereochemistry. Removal of sulfonyl groups in one step using LiEt₃BH/(dppp)PdCl₂ valuably reduced both the total number of synthetic steps and the formation of isomeric products resulting from double-bond migration and basic conditions.^{23,25} The resulting, pure synthetic polyprenols were shown to have a d.r. (*E/Z*) > 95% according to the characteristic allylic methyl group signals in ¹H NMR (see Figure S1); no unwanted isomeric product (<2%, ¹H NMR signals at δ 2.7, 5.9 ppm)³⁰ was detected.

These polyprenols were readily phosphorylated using mono-(tetrabutylammonium) phosphate (TBAP) activated with trichloroacetonitrile (TCA).³¹ We next attached just a single residue atypical glycan to provide a stringent test of the catalytic activity of PglB. Importantly, we used the sugar that would be found as the first N-linked residue in eukaryotic glycoproteins (but not prokaryotic and so not that normally employed by *Campylobacter*): GlcNAc. The resulting polyprenyl mono-phosphates 5a–g were therefore coupled to 2-acetamido-3,4,6-

Scheme 2. Syntheses of Lipid-linked Oligosaccharides and use in Glycopeptide Synthesis^a

^a(i) 5a–g, TBAP, TCA, DCM, RT; 5h, POCl₃, Et₃N, 2h. (ii) (1) CDI, DMF; (2) MeOH; (3) 6, DMF, RT, 3–5 days. (iii) NaOMe, MeOH. Yield over 3 steps: 8a = 17%, 8b = 23%, 8c = 9%, 8d = 17%, 8e = 9%, 8f = 38%, 8g = 29%, 8h = 32%, 13 = 22%, 14 = 30%. Extension reactions (blue arrows, 5–94%); see SI for further details.

tri-O-acetyl-2-deoxy-α-D-glucopyranose 1-phosphate (6) using carbonyldiimidazole (CDI)-mediated phosphoesterification.^{32,33} Deacetylation with catalytic NaOMe in MeOH (Zemplén conditions) gave the lipid pyrophosphate-linked saccharides (LPPS) 8a–g in 9–38% yield over three steps (Scheme 2).

With these first synthetic LPPS's in hand, 8a–h were then tested as substrates of PglB. The glycosylation of peptides bearing the required D/E-X-N-X-S/T consensus motif was determined by examining the increase of molecular weight (16%/6 M urea tricine-SDS-PAGE)³⁴ that corresponds to the addition of GlcNAc (Figure 2). An extract from *E. coli* LPPS containing *C. jejuni* heptasaccharide-linked undecaprenyl pyrophosphate was used as a positive control. Excitingly, 8a–e were active substrates for PglB-catalyzed N-glycosylation of the fluorescent peptide Tamra-DANYTK as indicated by the appearance of glycopeptide product bands with higher molecular weight consistent with the addition of GlcNAc. This importantly revealed that the lipid carrier for the substrate of PglB can contain as few as two *cis*-head repeating units. The activity of 8c and 8e as substrates for PglB also indicated that PglB can tolerate lipid carriers bearing *trans* geometry close to the hydroxyl terminus. However, activity was lost as the length of lipid became shorter than four prenyl units: nerol (1g)-PP-GlcNAc (8g), *cis,cis*-farnesol (1f)-PP-GlcNAc conjugate (8f), and citronellol-PP-GlcNAc conjugate (8h)^{32,33} did not show any detectable activity




Figure 2. Peptide and protein glycosylation. (a) Fluorescent electrophoretic analysis of peptide glycosylation with lipids (8a–h) (– = no lipid; + = lipid extracted and enriched from *E. coli* cells producing *C. jejuni* heptasaccharide-linked undecaprenyl pyrophosphate); [glycolipid] = [peptide] 20 μ M; [PglB] = 0.44 μ M. (b) ES-MS of *in vitro* N-linked protein (AcrA) glycosylation with 8c; >95% diglycosylation.

in the *in vitro* assay. These activities ‘mapped’ tight proximal-site activity and relaxed distal-site activity consistent with model shown in Figure S12.

These first kinetic parameters (Table 1) for PglB suggested key features. In particular, the variation of activity with lipid length in the substrate is strikingly only dependent on K_M ; k_{cat} remains essentially unaltered. This suggests that the lipid may not play a primary role in catalytic turnover but is a key regulator of substrate uptake. This suggested too that *in vitro* reactions conducted at sufficiently high concentrations $>K_M$ would allow transfer efficiencies equal to those found for full length lipid substrates. This was valuably confirmed in synthetic reactions that allowed the synthesis of GlcNAc-ylated glycopeptide in yields >90% using 0.1 mM glycosyl donor substrate 8c with 20 μ M of acceptor peptide. These >90% reactions usefully extend^{17,18} the synthetic utility of PglB.

Having elucidated valuable plasticity toward unnatural lipid-variant substrates, we next examined glycan breadth beyond the atypical monosaccharide GlcNAc already demonstrated. Conjugates (13 and 14) that contain both unnatural sugar and lipid carrier (Scheme 2) were prepared by coupling nerylnerolphos-

phate (5d) with the 6-azido-GlcNAc (9) and 2-azidoGlcNAc (10, GlcNAz). These compounds would allow subsequent flexible postexpressional modifications on proteins that contain D/E-X-N-X-S/T tag via reaction of the introduced azide with a number of compatible methods. Both azido analogues (13 and 14) failed to undergo glycosylation with the peptide in the presence of PglB. The failure of these glycolipids to act as substrates may be explained by the use of nonpreferred moieties in both halves of these unnatural sugar-unnatural lipid conjugates. It may also suggest a particular lack of plasticity by PglB toward alterations at sugar sites C-2 or C-6; glycolipids 13 and 14 did not inhibit PglB glycosylations using 8c (see SI).

GlcNAc-ylated peptide could then be extended (Scheme 2) with the use of endoglycosidases^{35,36} (EndoS,³⁷ EndoA,^{15,38,39} Scheme 2) and glycosyltransferases (β -1,4-GalT).⁴⁰ This allowed ready access to differently elaborated glycopeptides bearing, e.g., LacNAc (94%), or the eukaryotic N-glycan core-pentasaccharide (64%). Finally, we then tested the ability of this system to glycosylate proteins. Using short GlcNAc-lipids 8c and 8e, we could effect *in vitro* glycosylation >95% at the two consensus Asn sites in the *C. jejuni* AcrA¹⁴ protein.

In conclusion, a wide variety of *cis*-polyisoprenol variants were chemically synthesized and studied for their binding specificity against PglB. For the first time, LPPS's with only a single sugar and lipid chain lengths as short as C20 and C30 have been shown to be effective substrates for PglB in glycosylating specific peptide motifs. This reveals unexpected breadth for PglB beyond the minimal C40 lipid-trisaccharide substrate determined previously.¹⁷ Our experimental catalytic data are consistent with previous crystallographic and modeling analyses. A closer examination of the lipid-binding pocket also reveals a relationship between the PglB structure and the chain length requirements that we have discovered here. The narrow pocket that precedes the hydrophobic groove is surrounded by polar residues Ser198, Ser201, Arg375. Longer lipid chains beyond the third isoprenyl unit may be required for increased affinity, by favorable interaction with the hydrophobic groove. This explains the observation that 8e was an active substrate, but 8f was not. Similar studies on the lipid carrier specificity of MurG have however shown a quite different trend, in which nerol (1g) and nerylnerol (1d) conjugates were much better substrates than those of longer lipids bearing repeating *cis* units.^{24,41,42} Investigation of the crystal structures of MurG and/or PglB with lipid carrier bound, once available, would shed light on these clear differences in lipid carrier specificities.

The discovery of the breadth of PglB and these accessible lipid carriers now effectively enables the synthesis of lipid-pyrophosphate-linked substrates suitable for the *in vitro* generation of tailor-made glycoproteins. Importantly, to our knowledge, this currently represents the only *in vitro* biocatalytic system for the formation of the vital GlcNAc- β -1-N-Asn linkage (and importantly can be driven to >95% on proteins, here for AcrA); the recently discovered *Methanococcus* AglB, e.g.,¹¹ does

Table 1. Kinetic Parameters for PglB with GlcNAc Lipids^a

glycolipid substrate	k_{cat} [min^{-1}]	K_M [mM]	k_{cat}/K_M [$\text{min}^{-1}\text{mM}^{-1}$]
8d GlcNAc-PP- ω Z ₃	0.0234 \pm 0.0021	0.077 \pm 0.016	0.30
8c GlcNAc-PP- ω EZ ₄	0.0231 \pm 0.0016	0.055 \pm 0.01	0.42
8a GlcNAc-PP-prenol ₈	0.0225 \pm 0.0021	0.034 \pm 0.01	0.66

^aUPLC using TAMRA-fluorescence intensity; substrate concentrations: [glycolipid] = 1, 5, 10, 50, 100, 200 μ M, [peptide] = 20 μ M; enzyme concentration [PglB] = 0.44 μ M; reaction time <2h, 30 $^{\circ}$ C; all conducted in duplicate.

not transfer GlcNAc and requires an unusual disaccharide. This discovery complements prior GalNAc transfer and confirms a predicted activity.¹⁸ Notably, WecA,⁴³ the enzyme that would generate PP-linked glycolipid substrates for PglB, is membrane-associated and cannot be readily exploited *in vitro*. *In vitro* biocatalytic installation of GlcNAc, shown here, also creates a useful precursor sugar site for carbohydrate-processing enzyme-mediated extension, as shown here (Scheme 2). The >90% *in vitro* efficiencies shown here therefore make PglB a highly viable synthetic biocatalyst for varied glycopolypeptides, coupled with substrate accessibility and potential for further enzymatic transformation.

■ ASSOCIATED CONTENT

Supporting Information

Full procedures. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

Ben.Davis@chem.ox.ac.uk

Author Contributions

[§]These authors contributed equally.

Notes

The authors declare the following competing financial interest(s): M.K. and A.F. are employees of Glycovaxyn. A patent has been filed and will afford inventors royalties, if licensed, in line with university guidelines.

■ ACKNOWLEDGMENTS

We thank the BBSRC (T.A.T.), Glycovaxyn (F.L., B.V., B.G.D.) for funding, Drs P. Carranza, C. Bich for method development and glycopeptide analysis, and Drs L. Gong, J. Wickens for HRMS analysis. B.G.D. is a Royal Society Wolfson Merit Research Award Recipient.

■ REFERENCES

- (1) Spiro, R. G. *Glycobiology* **2002**, *12*, 43R.
- (2) Walsh, C. T.; Garneau-Tsodikova, S.; Gatto, G. J. *Angew. Chem., Int. Ed.* **2005**, *44*, 7342.
- (3) Ohtsubo, K.; Marth, J. D. *Cell* **2006**, *126*, 855.
- (4) Szymanski, C. M.; Yao, R.; Ewing, C. P.; Trust, T. J.; Guerry, P. *Mol. Microbiol.* **1999**, *32*, 1022.
- (5) Young, N. M.; Brisson, J. R.; Kelly, J.; Watson, D. C.; Tessier, L.; Lanthier, P. H.; Jarrell, H. C.; Cadotte, N.; St Michael, F.; Aberg, E.; Szymanski, C. M. *J. Biol. Chem.* **2002**, *277*, 42530.
- (6) Linton, D.; Allan, E.; Karlyshev, A. V.; Cronshaw, A. D.; Wren, B. W. *Mol. Microbiol.* **2002**, *43*, 497.
- (7) Scott, N. E.; Parker, B. L.; Connolly, A. M.; Paulech, J.; Edwards, A. V. G.; Crossett, B.; Falconer, L.; Kolarich, D.; Djordjevic, S. P.; Hojrup, P.; Packer, N. H.; Larsen, M. R.; Cordwell, S. J. *Mol. Cell. Proteomics* **2011**, *10*, M000031.
- (8) Schwarz, F.; Lizak, C.; Fan, Y.-Y.; Fleurkens, S.; Kowarik, M.; Aebi, M. *Glycobiology* **2011**, *21*, 45.
- (9) Jervis, A. J.; Langdon, R.; Hitchen, P.; Lawson, A. J.; Wood, A.; Fothergill, J. L.; Morris, H. R.; Dell, A.; Wren, B.; Linton, D. *J. Bacteriol.* **2010**, *192*, 5228.
- (10) Ielmini, M. V.; Feldman, M. F. *Glycobiology* **2011**, *21*, 734.
- (11) Larkin, A.; Chang, M. M.; Whitworth, G. E.; Imperiali, B. *Nat. Chem. Biol.* **2013**, *9*, 367.
- (12) Glover, K. J.; Weerapana, E.; Numao, S.; Imperiali, B. *Chem. Biol.* **2005**, *12*, 1311.
- (13) Wacker, M.; Feldman, M. F.; Callewaert, N.; Kowarik, M.; Clarke, B. R.; Pohl, N. L.; Hernandez, M.; Vines, E. D.; Valvano, M. A.; Whitfield, C.; Aebi, M. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 7088.
- (14) Feldman, M. F.; Wacker, M.; Hernandez, M.; Hitchen, P. G.; Marolda, C. L.; Kowarik, M.; Morris, H. R.; Dell, A.; Valvano, M. A.; Aebi, M. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 3016.
- (15) Schwarz, F.; Huang, W.; Li, C.; Schulz, B. L.; Lizak, C.; Palumbo, A.; Numao, S.; Neri, D.; Aebi, M.; Wang, L.-X. *Nat. Chem. Biol.* **2010**, *6*, 264.
- (16) Wacker, M.; Linton, D.; Hitchen, P. G.; Nita-Lazar, M.; Haslam, S. M.; North, S. J.; Panico, M.; Morris, H. R.; Dell, A.; Wren, B. W.; Aebi, M. *Science* **2002**, *298*, 1790.
- (17) Chen, M. M.; Weerapana, E.; Ciepihal, E.; Stupak, J.; Reid, C. W.; Swiezewska, E.; Imperiali, B. *Biochemistry* **2007**, *46*, 14342.
- (18) Li, L.; Woodward, R.; Ding, Y.; Liu, X.-w.; Yi, W.; Bhatt, V. S.; Chen, M.; Zhang, L.-w.; Wang, P. G. *Biochem. Biophys. Res. Commun.* **2010**, *394*, 1069.
- (19) Sato, K.; Inoue, S.; Onishi, A.; Uchida, N.; Minowa, N. *J. Chem. Soc., Perkin Trans. 1* **1981**, 761.
- (20) Sato, K.; Miyamoto, O.; Inoue, S.; Furusawa, F.; Matsushashi, Y. *Chem. Lett.* **1983**, *12*, 725.
- (21) Jaenicke, L.; Siegmund, H. *Biol. Chem. Hoppe-Seyler* **1986**, *367*, 787.
- (22) Inoue, S.; Kaneko, T.; Takahashi, Y.; Miyamoto, O.; Sato, K. *J. Chem. Soc., Chem. Commun.* **1987**, 1036.
- (23) Grassi, D.; Lippuner, V.; Aebi, M.; Brunner, J.; Vasella, A. *J. Am. Chem. Soc.* **1997**, *119*, 10992.
- (24) Chen, L.; Men, H.; Ha, S.; Ye, X.-Y.; Brunner, L.; Hu, Y.; Walker, S. *Biochemistry* **2002**, *41*, 6824.
- (25) Chang, Y.-F.; Liu, C.-Y.; Guo, C.-W.; Wang, Y.-C.; Fang, J.-M.; Cheng, W.-C. *J. Org. Chem.* **2008**, *73*, 7197.
- (26) Meng, F.-C.; Chen, K.-T.; Huang, L.-Y.; Shih, H.-W.; Chang, H.-H.; Nien, F.-Y.; Liang, P.-H.; Cheng, T.-J. R.; Wong, C.-H.; Cheng, W.-C. *Org. Lett.* **2011**, *13*, 5306.
- (27) Heseck, D.; Lee, M.; Zajiček, J.; Fisher, J. F.; Mobashery, S. *J. Am. Chem. Soc.* **2012**, *134*, 13881.
- (28) Shih, H.-W.; Chang, Y.-F.; Li, W.-J.; Meng, F.-C.; Huang, C.-Y.; Ma, C.; Cheng, T.-J. R.; Wong, C.-H.; Cheng, W.-C. *Angew. Chem., Int. Ed.* **2012**, *51*, 10123.
- (29) Lizak, C.; Gerber, S.; Numao, S.; Aebi, M.; Locher, K. P. *Nature* **2011**, *474*, 350.
- (30) Jaenicke, L.; Siegmund, H.-U. *Chem. Phys. Lipids* **1989**, *51*, 159.
- (31) Danilov, L. L.; Druzhinina, T. N.; Kalinchuk, N. A.; Maltsev, S. D.; Shibaev, V. N. *Chem. Phys. Lipids* **1989**, *51*, 191.
- (32) Bernardes, G. J. L.; Davis, B. G. unpublished results, University of Oxford, 2007.
- (33) Bernardes, G. J. L.; Kikkeri, R.; Maglinao, M.; Laurino, P.; Collot, M.; Hong, S. Y.; Lepenies, B.; Seeberger, P. H. *Org. Biomol. Chem.* **2010**, *8*, 4987.
- (34) Schagger, H. *Nat. Protoc.* **2006**, *1*, 16.
- (35) Wang, L.-X. *Carbohydr. Res.* **2008**, *343*, 1509.
- (36) Rich, J. R.; Withers, S. G. *Nat. Chem. Biol.* **2009**, *5*, 206.
- (37) Goodfellow, J. J.; Baruah, K.; Yamamoto, K.; Bonomelli, C.; Krishna, B.; Harvey, D. J.; Crispin, M.; Scanlan, C. N.; Davis, B. G. *J. Am. Chem. Soc.* **2012**, *134*, 8030.
- (38) Fernández-González, M.; Boutureira, O.; Bernardes, G. J.; Chalker, J. M.; Young, M.; Errey, J.; Davis, B. G. *Chem. Sci.* **2010**, *1*, 709.
- (39) Lomino, J. V.; Naegeli, A.; Orwenyo, J.; Amin, M. N.; Aebi, M.; Wang, L.-X. *Bioorg. Med. Chem.* **2013**, *21*, 2262.
- (40) Gamblin, D. P.; Garnier, P.; van Kasteren, S.; Oldham, N. J.; Fairbanks, A. J.; Davis, B. G. *Angew. Chem., Int. Ed.* **2004**, *43*, 828.
- (41) Ye, X.-Y.; Lo, M.-C.; Brunner, L.; Walker, D.; Kahne, D.; Walker, S. *J. Am. Chem. Soc.* **2001**, *123*, 3155.
- (42) Liu, C.-Y.; Guo, C.-W.; Chang, Y.-F.; Wang, J.-T.; Shih, H.-W.; Hsu, Y.-F.; Chen, C.-W.; Chen, S.-K.; Wang, Y.-C.; Cheng, T.-J.; Ma, C.; Wong, C.-H.; Fang, J.-M.; Cheng, W.-C. *Org. Lett.* **2010**, *12*, 1608.
- (43) Lehrer, J.; Vigeant, K. A.; Tatar, L. D.; Valvano, M. A. *J. Bacteriol.* **2007**, *189*, 2618.